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Letters to the Editor
Anti-Ro/SSA autoantibodies
over time in mothers of
children with congenital
complete heart block
Sir,
It is commonly assumed that the titer of anti-
Ro/SSA antibodies remains stable over the
years, but data in the literature are scanty (1-
4). Congenital heart block (CHB) is a multi-
disciplinary field; although anti-Ro/SSA an-
tibodies appear to be pathogenically linked
to it (5-7), the cardiological literature often
describes CHB mothers presumed to be anti-
Ro/SSA negative (8). The aim of this study
was to follow the titers of anti-Ro/SSA anti-
bodies in 11 CHB mothers over a long pe-
riod of time to see whether they remained
stable and whether any of the mothers’ titers
turned negative over time.
CHB was detected in utero r at birth. Table
I shows the year of each index delivery. Sera
were first available in 1989, and from then
on sera were tested serially. Antibodies to Ro/
SSA were determined by counterimmuno-
electrophoresis (CIE) and immunoblotting
using a human spleen extract as substrate, as
previously described (9). The fine specificity
and the titer of the anti-Ro response were also
determined by ELISA against 52 and 60 kD
recombinant proteins (Eurodiagnostica B.V.,
Arnhen, The Netherlands).
The results of our study are shown in Table
I. Eight out of 11 sera were positive by CIE
when first tested. Seven of these 8 remained
positive, while only the patient with a very
weak 1:2 anti-Ro titer lost the precipitin.
Semiquantitative evaluations of anti-Ro titers
by CIE showed slight fluctuations in each
patient. Serial testing detected variations in
the titer not greater than two dilutions. All 8
sera which were positive on IB showed reac-
tivity to the 52 kD protein, 6 being isolated
and 2 being associated with anti-60 kD reac-
tivity. All of the sera were initially positive
by 52 kD Ro ELISA. Anti-60 kD Ro ELISA
was initially positive in 6 mothers, but dur-
ing the follow-up 4 became negative, al-
though CIE remained positive with stable
titers.
As is usual in CHB, the mothers we studied
for the most part had only minor symptoms
(arthralgias, dry eyes, and photosensitivity)
and as a group they remained clinically sta-
ble over time. Therefore we could not relate
fluctuations in the titers to clinical events.
Overall, 10 out of 11 mothers remained posi-
tive for anti-Ro/SSA antibodies. However,
this was true only when a wide panel of as-
says was employed. One mother who was
positive at a low titer for anti-52 kD eight
years after delivery became negative three
Table I. Successive anti-Ro/SSA antibody titers in 11 CHB mothers.
Index Serum Anti-Ro/SSA ELISA ELISA
Mother delivery dates CIE titer by CIE IB Ro52 kD* Ro60 kD°
BE 1969 04.17.89 Ro+La 1:16 52 kD 74 14
11.17.89 1:32 61 10
30.09.93 1:16 63 15
07.05.94 1:16 44 12
06.11.96 1:8 51 11
03.09.98 1:16 36 8
FR 1976 03.15 89 Ro 1:2 52 kD 972 33
08.08.91 Neg Neg 87 9
08.25.94 Neg Neg 68 2
04.16.98 Neg Neg 45 < 1
Fl 1976 06.12.92 Ro+La 1:64 52 kD > 4000 25
07.15.94 Ro 1:64 > 4000 22
09.21.95 1:64 > 4000 19
04.17.98 1:32 > 4000 12
GC 1970 09.09.91 Neg Neg 105 9
07.05.94 Neg 71 6
06.11.96 Neg 167 5
GE 1992 09.22.92 Ro+La 1:16 52 kD 520 20
09.30.93 1:16 > 4000 16
10.06.94 1:16 > 4000 7
04.24.98 1:16 > 4000 10
LM 1992 02.22.92 Ro 1:128 60+52kD 390 12
03.18.93 1:64 527 11
09.21.94 1:64 389 9
04.20.98 1:64 3520 3
MG 1969 07.02.92 Ro+La 1:256 60+52kD > 4000 177
05.11.93 Ro+La 1:128 > 4000 500
05.30 94 Ro+La 1:256 > 4000 117
01.30.95 1:512 > 4000 83
10.25.95 1:512 > 4000 86
06.12.96 1:256 > 4000 67
04.14.98 1:512 > 4000 64
MF 1983 02.04.91 Neg Neg 83 13
07.19.94 Neg 30 2
PV 1960 15.04.89 Neg 52 kD 93 12
07.09.91 Neg 80 8
SG 1972 07.05.91 Ro 1:4 161 21
09.03.93 Ro 1:8 Neg 238 22
07.04.94 Ro 1:4 152 11
06.11.96 Ro 1:8 294 16
04.15.98 Ro 1:16 218 13
TS 1990 04.16.90 Ro 1:64 52 kD > 4000 53
06.25.91 Ro 1:64 52 kD > 4000 87
06.02.92 Ro 1:32 > 4000 88
06.29.93 Ro 1:128 > 4000 165
06.14.94 Ro 1:128 > 4000 306
09.11.95 Ro 1:128 > 4000 280
02.13.96 Ro 1:256 > 4000 856
04.16.98 Ro 1:128 > 4000 855
* Normal value < 34 AU/ml; °normal value < 16 AU/ml.
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years later; this was the only woman who
remained asymptomatic throughout the fol-
low-up.
Data in the literature regarding fluctuations
in the titer of anti-Ro/SSA antibodies are
scanty and conflicting. Some studies have re-
ported a correlation between the changing in
anti-Ro titer and disease activity (2-4), but
this has not been confirmed by others (1).
Tseng et al. (10) studied the immunoblot pro-
file of anti-SSA/Ro and SSB/La antibodies
over time in mothers whose children had neo-
natal lupus, and found that the fine specificity
of these antibodies, as assessed by immuno-
blot, was highly stable for years; no data con-
cerning fluctuations of the antibody titers was
given.
Our study therefore represents the first at-
tempt to assess fluctuations in the titer of anti-
Ro/SSA antibodies in a group of CHB mo-
thers by ELISA. Our findings hint at some
interesting conclusions. First of all, in the
majority of this sample of clinically stable
anti-Ro/SSA positive mothers, anti-Ro/SSA
antibody titers (particularly anti-Ro 52) re-
mained stable over time, and fluctuations
were not necessarily related to clinical events.
Secondly, the overall positivity for antibod-
ies remained constant over a very long pe-
riod of time, averaging 19.6 years from the
index delivery. Thirdly, and particularly im-
portant in the multi-disciplinary field of CHB,
anti-Ro/SSA antibodies were persistently
positive over the years only when a wide
panel of assays was employed, while a more
restricted investigation may incorrectly clas-
sify the CHB mother as anti-Ro/SSA nega-
tive.
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Bilateral optic neuritis in
ankylosing spondylitis
Sir,
Ocular involvement in ankylosing spondyli-
tis is common, particularly in uveitis. It oc-
curs in 25-30% of patients at some point dur-
ing the course of their disease (1). However,
involvement of the retina or optic nerve is
very rare. We describe here a patient with
ankylosing spondylitis and bilateral optic
neuritis.
In April 1992, a 42-year-old woman was seen
at the Rheumatology Clinic of Seoul National
University Hospital because of low back pain.
In 1981, she developed pain in the lower back
and buttocks, which improved with the in-
termittent administration of over-the-coun-
ter medications. In early 1992, she visited a
hospital due to posterior neck pain which was
diagnosed as ankylosing spondylitis.
In April 1992 she was referred to our hospi-
t l with pain and stiffness in the neck, mid-
dle and lower back, and right hip. A com-
plete blood cell count showed white blood
cells 10,900/mm3 (segmented neutrophils
71%, lymphocytes 24%, monocytes 2%, eo-
sinophils 2%, and basophils 1%), hemoglobin
11.9 g/dl, and platelets 230,000/mm3. The
Westergren erythrocyte sedimentation rate
(ESR) was 65 mm/hr. Rheumatoid factor was
negative. Antinuclear antibody was weakly
positive at 1:40 dilution. Radiographs of the
pelvis and lumbar spine showed bilateral sa-
croiliitis (Fig. 1) and syndesmophytes. An
HLA-B27 test was positive.
Fenoprofen 600 mg tid and sulfasalazine 0.5g
bid were prescribed, which led to gradual
improvement of the arthralgia. In March
1997, her neck pain worsened with a West-
ergren ESR of 83 mm/hr. Fenoprofen was
replaced by indomethacin. She remained rela-
tively well until July 1997 when she devel-
oped a visual disturbance in the left eye. She
visited a private ophthalmology clinic, where
a visual field examination revealed a defect
in inferior altitudinal visual field. This visual
deficit improved slowly and spontaneously,
but two weeks later she suddenly developed
blindness accompanied by severe pain in the
right eye, together with frontal headache.
Ophthalmologic examination at our hospital
revealed that the visual acuity was finger
count in the right eye and 0.8 in the left. There
was an afferent pupillary defect in the right
eye. The intraocular pressures and slit-lamp
examination results were unremarkable in
both eyes. The disc was not edematous on
ophthalmoscopic examination. The patient’s
ESR was 52 mm/hr and her C-reactive pro-
tein was 0.6 mg/dl (normal < 0.5). Fluores-
cent angiography showed a faint filling de-
fect around the disc margin in both eyes. A
visual evoked potential (VEP) study showed
prolonged latency of deflection. Computed
tomography and magnetic resonance imaging
of the brain were normal.
The patient was admitted to hospital with a
diagnosis of optic neuritis and received i.v.
methylprednisolone pulse therapy (1 g/day)
Fig. 1. AP view of the pelvis shows bilateral
sacroiliitis.
